Lactobacillus paracasei GMNL-133 for Atopic Dermatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases, such as atopic dermatitis, often come with side effects and are not highly effective in eradicating symptoms, as they rely on anti-histamines and steroid therapies, which can lead to long-term side effects and recurrence of symptoms.
Innovation Solution
An oral composition containing a novel isolated Lactobacillus paracasei strain GMNL-133, which stimulates IFN-γ secretion to modulate the immune response, thereby reducing allergic symptoms by promoting a Th1 response over Th2, is used to treat allergic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If anti-histamines are used to treat allergic symptoms, then redness, itching and swelling are reduced, but side effects such as diminished alertness, slowed reaction times and somnolence occur
Solution Approach 1:
The patent uses probiotics (Lactobacillus sp., Bifidobacterium sp., and other beneficial microorganisms) as an intermediary substance to modulate the immune system and reduce allergic responses. Instead of directly blocking histamine receptors with anti-histamines, the probiotics work through the gut-immune axis to decrease IgE production and reduce mast cell degranulation, thereby alleviating allergic symptoms without causing sedative side effects
Solution Approach 2:
The patent replaces the pharmacological mechanism of anti-histamines (chemical blockade of H1 receptors) with a biological mechanism involving probiotics that modulate immune response through microbial-metabolite-immune cell interactions. This substitution uses living microorganisms and their metabolic products to achieve therapeutic effects through immune regulation rather than direct receptor antagonism
2Object-affected harmful factors
If topical steroid therapy is used to treat atopic dermatitis, then inflammatory symptoms are reduced, but long-term use causes skin atrophy, thinning, pigmentation changes, hair growing, and acne
Solution Approach 1:
The patent introduces probiotics as an intermediary therapeutic agent that acts systemically through the gut-skin axis. The probiotics modulate immune responses and reduce inflammation remotely, avoiding direct contact with the skin and thereby preventing local side effects such as atrophy and thinning that occur with topical steroid application
Solution Approach 2:
The patent leverages the gut microbiome as a beneficial pathway to treat skin conditions. By administering probiotics orally, the therapy converts the gastrointestinal tract into a therapeutic delivery system that produces anti-inflammatory effects systemically, turning a potential source of inflammation into a beneficial route for delivering therapeutic effects without skin exposure
3Ease of operation
If conventional allergy therapies are used, then some symptom relief is achieved, but symptoms recur frequently after stopping treatment and are difficult to eradicate
Solution Approach 1:
The patent employs probiotics to perform preliminary action by modulating the immune system before allergic responses are fully activated. By establishing a balanced gut microbiome and priming immune regulation in advance, the therapy creates long-lasting immunological memory and sustained tolerance, preventing recurrence rather than merely suppressing symptoms temporarily
Solution Approach 2:
The patent enables the body's own immune system to serve itself by restoring proper immune regulation through probiotic intervention. The probiotics stimulate the body's inherent mechanisms for maintaining immune balance, including regulatory T cell function and anti-inflammatory cytokine production, allowing the immune system to self-regulate and maintain long-term remission without continuous external intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Lactobacillus paracasei strain GMNL-133 composition significantly decreases inflammatory markers and improves symptoms in allergic mouse models by enhancing Th1 immune responses and inhibiting Th2 responses, offering a safer and more effective treatment option compared to conventional therapies.
Implementation Method 1
Lactic acid bacteria is a group of gram-positive facultative anaerobic bacteria, which is commonly found in the human gastrointestinal tract and vagina, and can ferment sugar to lactic acid as major metabolites
Data Source
Figure 1
Figure 2
Figure 3~4A
AI summary
An isolated Lactobacillus paracasei strain GMNL-133 is disclosed, which was deposited in the China Center for Type Culture Collection (CCTCC) under the accession number of CCTCC M 2011331 is disclosed. The isolated Lactobacillus paracasei strain GMNL-133 is used for preparing a composition for use as a medicament, and in particular for the treatment of atopic dermatitis or other allergic diseases in an effective amount. And a composition for use in the treatment of atopic dermatitis or other allergic diseases comprises an effective amount of the Lactobacillus paracasei strain GMNL-133 is also disclosed.